ScripDespite hailing OG-6219 as its “biggest potential opportunity” during its fourth-quarter earnings call in Feb 2025, Organon has decided to discontinue the drug’s development owing to its poor performa
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. SunRock, Escugen Partner To Develo
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Taiho Sends Benz LSD1 Inhibitor Fo
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C